0001410939-22-000048.txt : 20220406
0001410939-22-000048.hdr.sgml : 20220406
20220406181119
ACCESSION NUMBER: 0001410939-22-000048
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220404
FILED AS OF DATE: 20220406
DATE AS OF CHANGE: 20220406
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SBLENDORIO GLENN
CENTRAL INDEX KEY: 0001277478
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36080
FILM NUMBER: 22811647
MAIL ADDRESS:
STREET 1: 3 TIMES SQAURE, 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IVERIC bio, Inc.
CENTRAL INDEX KEY: 0001410939
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208185347
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: (609) 474-6755
MAIL ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Ophthotech Corp.
DATE OF NAME CHANGE: 20070828
4
1
wf-form4_164928306290708.xml
FORM 4
X0306
4
2022-04-04
0
0001410939
IVERIC bio, Inc.
ISEE
0001277478
SBLENDORIO GLENN
C/O IVERIC BIO, INC.
8 SYLVAN WAY
PARSIPPANY
NJ
07054
1
1
0
0
CEO
Common Stock
2022-04-04
4
S
0
50000
18.7561
D
229689
D
The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. For a full discussion regarding the details of the Rule 10b5-1 trading plan adopted by the Reporting Person, refer to the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the the Securities and Exchange Commission on March 30, 2022.
/s/ Todd Anderman, as Attorney-in-Fact for Glenn P. Sblendorio
2022-04-06